FDA Warning Letter to Peak Performance Peptides (2026-08-24) — Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
In short: The FDA Center for Drug Evaluation and Research issued Warning Letter 735127 on August 24, 2026, to Peak Performance Peptides (founder Jeffrey Deng, Phoenix, AZ) regarding unapproved new drugs sold via pppepz.com. The letter identifies six products—Bac water, GLP-3R (retatrutide), Semaglutide, SS-31, PT-141, and Tesamorelin—as unapproved new drugs under section 505(a) of the FD&C Act, with website claims describing their intended use for metabolic regulation, weight management, glycemic control, mitochondrial function, sexual arousal, and other therapeutic effects. The FDA notes injectable products pose particular public health concern due to direct delivery into the body, and directs the firm to promptly address violations or face seizure and injunction.
Argus analysis
# FDA Warning Letter Analysis: Peak Performance Peptides
**Company and Violations**
Peak Performance Peptides, a Phoenix-based firm operated by founder Jeffrey Deng, received an FDA Warning Letter on August 24, 2026, from the Center for Drug Evaluation and Research (CDER). The agency identified six products sold through the company's website as unapproved new drugs: retatrutide (marketed as "GLP-3R"), semaglutide, SS-31 (elamipretide), PT-141, tesamorelin, and bacteriostatic water ("Bac water"). The FDA's review of pppepz.com in July 2026 found that these injectable products were being marketed with claims related to metabolic regulation, body weight management, glucose control, mitochondrial function, sexual arousal, and growth hormone stimulation—characteristics that classify them as drugs under federal law.
**Regulatory Citations**
The violations center on sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)), along with the definition of drugs under section 201(g)(1) (21 U.S.C. 321(g)(1)). These provisions require FDA approval before introducing new drugs into interstate commerce. The agency noted that despite labeling claiming "research use only" and "not for human consumption," website content describing therapeutic effects established intent for human use. Injectable drug products present particular concern because they bypass natural defenses against contamination and pathogens.
**Response Timeline and Compliance Watch**
Peak Performance Peptides has fifteen business days from receipt to submit a written response to FDAAdvisory@fda.hhs.gov detailing corrective actions and preventative measures. Compliance officers monitoring this case should watch for whether the company ceases sales, reformulates labeling, or seeks approval pathways. The FDA indicated that failure to address violations adequately may result in seizure or injunction. Warning letters addressing unapproved drug sales typically precede enforcement action if the recipient does not demonstrate substantive compliance changes.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Peak Performance Peptides MARCS-CMS 735127 — August 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Jeffrey Deng Recipient Title Founder Peak Performance Peptides 3935 E Rough Rider Rd Unit 1016 Phoenix , AZ 85050 United States contact@pppepz.com (b)(6), (b)(7)(C) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 24, 2026 WARNING LETTER Reference Number: 735127 To Jeffrey Deng: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions. FDA Review Violations were identified and documented during a review of your website pppepz.com in July 2026. Based on our review, “Bac water,” “GLP-3R” (retatrutide), “Semaglutide,” “SS-31,” “PT-141,” and “Tesamorelin” 1 are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “Bac water,” “GLP-3R” (retatrutide), “Semaglutide,” “SS-31,” “PT-141,” and “Tesamorelin” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Peak Performance Peptides had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Peak Performance Peptides as of 2026-09-01. Argus ingests new FDA enforcement records daily.
- What FDA violations was Peak Performance Peptides cited for?
- The FDA Warning Letter to Peak Performance Peptides (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Peak Performance Peptides (2026-08-24) — Unapproved New Drugs/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-peak-performance-peptides-2026-08-24-unapproved-drug
"FDA Warning Letter to Peak Performance Peptides (2026-08-24) — Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-peak-performance-peptides-2026-08-24-unapproved-drug.
Argus HQ Research. "FDA Warning Letter to Peak Performance Peptides (2026-08-24) — Unapproved New Drugs/Misbranded." Digital Empire Holdings LLC. Accessed September 4, 2026. https://argushq.ai/fda/warning-letter/fda-wl-peak-performance-peptides-2026-08-24-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_peak_performance_peptides_2026_08_24_unapproved_drug_2026,
title = {FDA Warning Letter to Peak Performance Peptides (2026-08-24) — Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-peak-performance-peptides-2026-08-24-unapproved-drug},
note = {Accessed: September 4, 2026}
}